Login to Your Account

Financings Roundup

Revance Adds $33M for BoNTA Alternative to Botox

By Marie Powers
Staff Writer

Wednesday, April 3, 2013
Privately held Revance Therapeutics Inc. raised $33 million in a Series E financing and converted $71 million in convertible debt into Series E preferred stock, aiming to complete U.S. Phase III trials for lead compound RT001, a physician-applied topical botulinum toxin type A (BoNTA), in the lead indication of lateral canthal lines, better known as crow's feet.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription